AIM ImmunoTech Inc
aimimmuno.comAIM ImmunoTech Inc (NYSE American: AIM) is a biopharmaceutical company focused on the research, development, and commercialization of two primary drug candidates: Ampligen (rintatolimod), a TLR3 agonist immunotherapy, and Alferon N Injection, a natural interferon alpha. The company generates minimal product revenue, relying primarily on equity financing, including an at-the-market offering agreement with Maxim Group LLC for up to $3,000,000 in common stock sales as of April 1, 2025. AIM operates as a clinical-stage company with no meaningful commercial revenue base, funding operations through capital markets rather than product sales. Ampligen is under investigation across multiple indications including ME/CFS, pancreatic cancer, post-COVID conditions, Ebola virus disease (FDA Orphan Drug Designation granted November 2022), and Alzheimer's disease. Alferon N Injection is approved in Argentina under the brand name Naturaferon, with commercialization efforts ongoing pending regulatory renewal. The company holds a 5,210-square-foot R&D facility at the New Jersey Bioscience Center and an office in Riverton.
Products & Services
Ampligen (rintatolimod): investigational TLR3 agonist with clinical programs in ME/CFS, pancreatic cancer, post-COVID conditions, Ebola virus disease, and Alzheimer's disease. Alferon N Injection (Naturaferon in Argentina): natural interferon alpha product with ANMAT approval for sale in Argentina; approval renewal pending as of the FY2025 10-K.
Revenue Model
AIM ImmunoTech has no significant recurring product revenue. Operations are funded through equity issuances, including an at-the-market facility with Maxim Group LLC (up to $3,000,000 in common stock, established April 1, 2025). Limited product sales of Ampligen and Alferon N Injection exist but are not a material revenue source per the FY2025 10-K filed March 27, 2026.
Customers & Markets
End markets include patients with ME/CFS, pancreatic cancer, post-COVID conditions, Ebola virus disease, and Alzheimer's disease. Early access program patients in the Netherlands accessed Ampligen through myTomorrows. Argentine patients access Alferon N Injection through distribution partner Filaxis (formerly GP Pharm), though Filaxis has issued a termination notice for that project.
Geographic Exposure
Primary operations in the United States, with R&D facilities in New Jersey and offices in Riverton. International exposure includes Argentina (Alferon N Injection/Naturaferon commercialization) and the Netherlands (Ampligen early access program via myTomorrows). Research collaborations with institutions in Italy (University of Cagliari) and Japan (National Institute of Infectious Diseases and Shionogi & Co., Ltd.).
Financial Snapshot
Loading...
